7M2N
Crystal structure of Human Lactate Dehydrogenase A with Inhibitor Compound 15
Summary for 7M2N
| Entry DOI | 10.2210/pdb7m2n/pdb |
| Descriptor | L-lactate dehydrogenase A chain, 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE, SULFATE ION, ... (8 entities in total) |
| Functional Keywords | oxidoreductase |
| Biological source | Homo sapiens (Human) |
| Total number of polymer chains | 4 |
| Total formula weight | 162655.83 |
| Authors | Gumpena, R.,Ding, J.,Powell, D.A.,Lowther, W.T. (deposition date: 2021-03-17, release date: 2021-07-14, Last modification date: 2025-09-17) |
| Primary citation | Cox, J.H.,Boily, M.O.,Caron, A.,Sheng, T.,Wu, J.,Ding, J.,Gaudreault, S.,Chong, O.,Surendradoss, J.,Gomez, R.,Lester, J.,Dumais, V.,Li, X.,Gumpena, R.,Hall, M.D.,Waterson, A.G.,Stott, G.,Flint, A.J.,Moore, W.J.,Lowther, W.T.,Knight, J.,Percival, M.D.,Tong, V.,Oballa, R.,Powell, D.A.,King, A.J. Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment. J Am Soc Nephrol, 36:1535-1547, 2025 Cited by PubMed Abstract: Primary hyperoxalurias are genetic diseases defined by elevated hepatic oxalate production and higher incidence of kidney stones. Lactate dehydrogenase A catalyzes the final and committed step in hepatic oxalate synthesis and represents a potential therapeutic target for primary hyperoxalurias. CHK-336 is a liver-targeted, small-molecule lactate dehydrogenase A inhibitor with potential to treat diseases associated with elevated oxalate production. PubMed: 40193200DOI: 10.1681/ASN.0000000690 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (2.5 Å) |
Structure validation
Download full validation report
